Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Scheffler

Showing results (151-160 of 207) with videos related to

Pageof 21
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinomaRichard Riedel, Sebastian Michels, Carina Heydt, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 8, 2017
Understanding band gaps of solids in generalized Kohn-Sham theoryJohn P Perdew, Weitao Yang, Kieron Burke, et al.
Journal of Chemical Theory and Computation|December 9, 2015
GW100: Benchmarking G0W0 for Molecular SystemsMichiel J van Setten, Fabio Caruso, Sahar Sharifzadeh, et al.
Clinical Lung Cancer|December 12, 2018
Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine PETDiana S Y Abdulla, Matthias Scheffler, Vanessa Brandes, et al.
Journal of Magnetic Resonance Imaging : JMRI|May 25, 2021
Fully Automated MR Detection and Segmentation of Brain Metastases in Non-small Cell Lung Cancer Using Deep LearningStephanie T Jünger, Ulrike Cornelia Isabel Hoyer, Diana Schaufler, et al.
NPJ Precision Oncology|June 7, 2018
<i>ALK</i><sup>G1269A</sup> mutation as a potential mechanism of acquired resistance to crizotinib in an <i>ALK</i>-rearranged inflammatory myofibroblastic tumorSebastian Y F Michels, Andreas H Scheel, Thomas Wündisch, et al.
JCO Precision Oncology|February 9, 2022
Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With <i>ROS1</i>-Rearranged NSCLCSebastian Michels, Matthias Scheffler, Svenja Wagener, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 23, 2015
Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same PatientMatthias Scheffler, Sabine Merkelbach-Bruse, Marc Bos, et al.
Oncoimmunology|July 29, 2016
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterationsAndreas H Scheel, Sascha Ansén, Anne M Schultheis, et al.
Plos One|May 17, 2011
Benchmarking of mutation diagnostics in clinical lung cancer specimensSilvia Querings, Janine Altmüller, Sascha Ansén, et al.
Pageof 21

Showing results (151-160 of 207) with videos related to

Sort By:
Pageof 21
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinomaRichard Riedel, Sebastian Michels, Carina Heydt, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 8, 2017
Understanding band gaps of solids in generalized Kohn-Sham theoryJohn P Perdew, Weitao Yang, Kieron Burke, et al.
Journal of Chemical Theory and Computation|December 9, 2015
GW100: Benchmarking G0W0 for Molecular SystemsMichiel J van Setten, Fabio Caruso, Sahar Sharifzadeh, et al.
Clinical Lung Cancer|December 12, 2018
Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine PETDiana S Y Abdulla, Matthias Scheffler, Vanessa Brandes, et al.
Journal of Magnetic Resonance Imaging : JMRI|May 25, 2021
Fully Automated MR Detection and Segmentation of Brain Metastases in Non-small Cell Lung Cancer Using Deep LearningStephanie T Jünger, Ulrike Cornelia Isabel Hoyer, Diana Schaufler, et al.
NPJ Precision Oncology|June 7, 2018
<i>ALK</i><sup>G1269A</sup> mutation as a potential mechanism of acquired resistance to crizotinib in an <i>ALK</i>-rearranged inflammatory myofibroblastic tumorSebastian Y F Michels, Andreas H Scheel, Thomas Wündisch, et al.
JCO Precision Oncology|February 9, 2022
Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With <i>ROS1</i>-Rearranged NSCLCSebastian Michels, Matthias Scheffler, Svenja Wagener, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 23, 2015
Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same PatientMatthias Scheffler, Sabine Merkelbach-Bruse, Marc Bos, et al.
Oncoimmunology|July 29, 2016
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterationsAndreas H Scheel, Sascha Ansén, Anne M Schultheis, et al.
Plos One|May 17, 2011
Benchmarking of mutation diagnostics in clinical lung cancer specimensSilvia Querings, Janine Altmüller, Sascha Ansén, et al.
Pageof 21